Prediction of neoadjuvant chemotherapy efficacy in breast cancer: integrating multimodal imaging and clinical features.

OBJECTIVES

To assess the predictive value of combining DCE-MRI, DKI, IVIM parameters, and clinical characteristics for neoadjuvant chemotherapy (NAC) efficacy in invasive ductal carcinoma.

METHODS

We conducted a retrospective study of 77 patients with invasive ductal carcinoma, analyzing MRI data collected before NAC. Parameters extracted included DCE-MRI (Ktrans, Kep, Ve, wash-in, wash-out, TTP, iAUC), DKI (MK, MD), and IVIM (D, D*, f). Differences between NAC responders and non-responders were assessed using t-tests or Mann-Whitney U tests. ROC curves and Spearman correlation analyses evaluated predictive accuracy.

RESULTS

NAC responders had higher DCE-MRI-Kep, DKI-MD, IVIM-D, and IVIM-f values. Non-responders had higher DCE-MRI-Ve, DKI-MK, IVIM-D (kurtosis, skewness, entropy), and IVIM-f (entropy). The mean DKI-MK had the highest AUC (0.724), and IVIM-D interquartile range showed the highest sensitivity (94.12%). Combined parameters had the highest AUC (0.969), sensitivity (94.12%), and specificity (90.70%). HER2 status (OR, 0.187; 95% CI: 0.038, 0.914; P = 0.038) and tumor margin (OR, 20.643; 95% CI: 2.892, 147.365; P = 0.003) were identified as independent factors influencing the lack of significant efficacy of neoadjuvant chemotherapy (NAC) in breast cancer.

CONCLUSIONS

Combining DCE-MRI, DKI, and IVIM parameters effectively predicts NAC efficacy, providing valuable preoperative assessment insights.

CLINICAL TRIAL NUMBER

Not applicable.